Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept treatment in polymyositis and dermatomyositis
2009-015957-20Phase 2Active
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in polymyositis (PM) and dermatomyositis (DM), sponsored by Karolinska University Hospital. Primary endpoint: IMACS responder rate at 6 months. Started Jan 2010; status: active.
02
Drugs
abatacept
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on 2009-015957-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015957-20.